Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Cantor Fitzgerald

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)'s stock had its "overweight" rating reissued by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $180.00 price objective on the specialty pharmaceutical company's stock. Cantor Fitzgerald's price objective suggests a potential upside of 57.78% from the company's previous close.

Several other equities analysts have also issued reports on JAZZ. UBS Group reduced their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating for the company in a report on Friday, March 1st. Piper Sandler raised their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an "overweight" rating in a research report on Wednesday, March 20th. Stifel Nicolaus boosted their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a "buy" rating in a report on Friday, March 15th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, January 30th. Finally, HC Wainwright lowered their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating on the stock in a research report on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $195.08.

Jazz Pharmaceuticals Stock Up 0.1 %

NASDAQ JAZZ traded up $0.08 on Wednesday, reaching $114.08. The company had a trading volume of 716,659 shares, compared to its average volume of 617,931. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The company's fifty day moving average is $121.66 and its 200 day moving average is $123.44. Jazz Pharmaceuticals has a 52-week low of $111.25 and a 52-week high of $147.45. The stock has a market capitalization of $7.19 billion, a P/E ratio of 18.64, a P/E/G ratio of 1.59 and a beta of 0.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1.01 billion. Sell-side analysts anticipate that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Philip L. Johnson purchased 12,000 shares of the firm's stock in a transaction dated Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares of the company's stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Corporate insiders own 4.40% of the company's stock.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Jazz Pharmaceuticals by 0.5% in the third quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company's stock valued at $825,705,000 after purchasing an additional 29,960 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Jazz Pharmaceuticals by 7.5% in the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company's stock worth $408,654,000 after buying an additional 184,124 shares during the last quarter. State Street Corp raised its position in shares of Jazz Pharmaceuticals by 1.8% during the 2nd quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company's stock valued at $294,106,000 after buying an additional 42,703 shares in the last quarter. LSV Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 2.4% during the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company's stock worth $307,055,000 after acquiring an additional 55,630 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company's stock worth $172,560,000 after acquiring an additional 100,349 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.